BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25744435)

  • 1. Survivin suppressor (YM155) enhances chemotherapeutic efficacy against canine histiocytic sarcoma in murine transplantation models.
    Yamazaki H; Takagi S; Hosoya K; Okumura M
    Res Vet Sci; 2015 Apr; 99():137-44. PubMed ID: 25744435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of a survivin suppressor YM155 on the chemoresistance of canine histiocytic sarcoma cells.
    Yamazaki H; Takagi S; Hosoya K; Okumura M
    Vet J; 2015 Sep; 205(3):375-80. PubMed ID: 26048444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor efficacy and biodistribution of liposomal sepantronium bromide (YM155), a novel small-molecule survivin suppressant.
    Kawano H; Shakushiro K; Nakata M; Kita A; Maeda A; Watanabe S; Sako K; Oku N
    Eur J Pharm Biopharm; 2014 Sep; 88(1):283-9. PubMed ID: 24993306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma.
    Yu Y; Zhao X; Zhang Y; Kang Y; Wang J; Liu Y
    Oncol Rep; 2015 Jul; 34(1):407-14. PubMed ID: 25955434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YM155 inhibits tumor growth and enhances chemosensitivity to cisplatin in osteosarcoma.
    Gao JZ; Chen FH; Wang L; Wei H; Meng SL
    Eur Rev Med Pharmacol Sci; 2015; 19(11):2062-9. PubMed ID: 26125270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silencing of survivin using YM155 induces apoptosis and chemosensitization in neuroblastomas cells.
    Liang H; Zhang L; Xu R; Ju XL
    Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2909-15. PubMed ID: 24254560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II, open-label trial of single-agent CCNU in dogs with previously untreated histiocytic sarcoma.
    Rassnick KM; Moore AS; Russell DS; Northrup NC; Kristal O; Bailey DB; Flory AB; Kiselow MA; Intile JL
    J Vet Intern Med; 2010; 24(6):1528-31. PubMed ID: 21155191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer.
    Yamanaka K; Nakata M; Kaneko N; Fushiki H; Kita A; Nakahara T; Koutoku H; Sasamata M
    Int J Oncol; 2011 Sep; 39(3):569-75. PubMed ID: 21674125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma.
    Kita A; Nakahara T; Yamanaka K; Nakano K; Nakata M; Mori M; Kaneko N; Koutoku H; Izumisawa N; Sasamata M
    Leuk Res; 2011 Jun; 35(6):787-92. PubMed ID: 21237508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.
    Nakahara T; Kita A; Yamanaka K; Mori M; Amino N; Takeuchi M; Tominaga F; Hatakeyama S; Kinoyama I; Matsuhisa A; Kudoh M; Sasamata M
    Cancer Res; 2007 Sep; 67(17):8014-21. PubMed ID: 17804712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YM155 enhances the cytotoxic activity of etoposide against canine osteosarcoma cells.
    Ong SM; Saeki K; Kok MK; Nakagawa T; Nishimura R
    J Vet Med Sci; 2019 Aug; 81(8):1182-1190. PubMed ID: 31308291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of Survivin Pathways by YM155 Inhibits Cell Death and Invasion in Oral Squamous Cell Carcinoma Cells.
    Zhang W; Liu Y; Li YF; Yue Y; Yang X; Peng L
    Cell Physiol Biochem; 2016; 38(6):2426-37. PubMed ID: 27287458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic antitumor activities of sepantronium bromide (YM155), a survivin suppressant, in combination with microtubule-targeting agents in triple-negative breast cancer cells.
    Kaneko N; Yamanaka K; Kita A; Tabata K; Akabane T; Mori M
    Biol Pharm Bull; 2013; 36(12):1921-7. PubMed ID: 24432379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual induction of apoptotic and autophagic cell death by targeting survivin in head neck squamous cell carcinoma.
    Zhang L; Zhang W; Wang YF; Liu B; Zhang WF; Zhao YF; Kulkarni AB; Sun ZJ
    Cell Death Dis; 2015 May; 6(5):e1771. PubMed ID: 26018732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
    Yamanaka K; Nakahara T; Yamauchi T; Kita A; Takeuchi M; Kiyonaga F; Kaneko N; Sasamata M
    Clin Cancer Res; 2011 Aug; 17(16):5423-31. PubMed ID: 21737502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Commitment toward cell death by activation of autophagy with survivin inhibitor YM155 in two canine squamous cell carcinoma cell lines with high expression of survivin.
    Miyamoto R; Tani H; Ikeda T; Saima H; Tamura K; Bonkobara M
    Res Vet Sci; 2021 Mar; 135():412-415. PubMed ID: 33160684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of dasatinib in a xenograft mouse model of canine histiocytic sarcoma and in vitro expression status of its potential target EPHA2.
    Ito K; Miyamoto R; Tani H; Kurita S; Kobayashi M; Tamura K; Bonkobara M
    J Vet Pharmacol Ther; 2018 Feb; 41(1):e45-e48. PubMed ID: 28833247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of an Orthotopic Intrasplenic Xenograft Mouse Model of Canine Histiocytic Sarcoma and Its Use in Evaluating the Efficacy of Treatment with Dasatinib.
    Takada M; Smyth LA; Hix JM; Corner SM; Kiupel M; Yuzbasiyan-Gurkan V
    Comp Med; 2019 Feb; 69(1):22-28. PubMed ID: 30717820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epirubicin in the treatment of canine histiocytic sarcoma: sequential, alternating and rescue chemotherapy.
    Mason SL; Finotello R; Blackwood L
    Vet Comp Oncol; 2018 Mar; 16(1):E30-E37. PubMed ID: 28621004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canine squamous cell carcinoma cell lines with high expression of survivin are sensitive to survivin inhibitor YM155.
    Miyamoto R; Kurita S; Tani H; Ikeda T; Ishizaka M; Saima H; Kobayashi M; Tamura K; Bonkobara M
    Vet J; 2018 Oct; 240():31-36. PubMed ID: 30268330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.